Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5269861
Max Phase: Preclinical
Molecular Formula: C20H27N3O3
Molecular Weight: 357.45
Associated Items:
ID: ALA5269861
Max Phase: Preclinical
Molecular Formula: C20H27N3O3
Molecular Weight: 357.45
Associated Items:
Canonical SMILES: C#CC(=O)NCC(=O)N1CCN(C(=O)C23CC4CC(CC(C4)C2)C3)CC1
Standard InChI: InChI=1S/C20H27N3O3/c1-2-17(24)21-13-18(25)22-3-5-23(6-4-22)19(26)20-10-14-7-15(11-20)9-16(8-14)12-20/h1,14-16H,3-13H2,(H,21,24)
Standard InChI Key: FBLBBVYSXUHSSN-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 357.45 | Molecular Weight (Monoisotopic): 357.2052 | AlogP: 0.62 | #Rotatable Bonds: 3 |
Polar Surface Area: 69.72 | Molecular Species: NEUTRAL | HBA: 3 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 6 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 12.44 | CX Basic pKa: 1.17 | CX LogP: 0.39 | CX LogD: 0.39 |
Aromatic Rings: 0 | Heavy Atoms: 26 | QED Weighted: 0.75 | Np Likeness Score: -0.87 |
1. Mader L, Watt SKI, Iyer HR, Nguyen L, Kaur H, Keillor JW.. (2023) The war on hTG2: warhead optimization in small molecule human tissue transglutaminase inhibitors., 14 (2.0): [PMID:36846370] [10.1039/d2md00378c] |
Source(1):